Jesteś w trybie podpowiedzi Wyłącz
Do szybkiego przemieszczania się między blokami

Jednostka: NewAmsterdam Pharma
LEI 984500B6549TF6E14D36

Nazwa organizacji
NewAmsterdam Pharma Co NV
Nazwa kraju
Holandia
Kraj rejestracji
Holandia
Branża
Produkcja leków i biotechnologii
Dług obligacyjny
-

poznaj najbardziej kompletną bazę danych

800 000

obligacje na całym świecie

Ponad 400

źródła kształtowania cen

80 000

akcje

9 000

ETF

najskuteczniej kontroluj swój portfel
skaner obligacji
Lista do obejrzenia
DODATEK Excel
Uzyskaj dostęp

Ostatnie dane na

Notowania

Zapytanie wysłano
Dostęp zamknięty
Wysłać zapytanie
Notowania dostarczane przez dostawców informacji mają charakter orientacyjny

Profil

NewAmsterdam Pharma operates as a pharmaceutical company. The Company focuses on the research and development of transformative therapies for cardio-metabolic diseases. NewAmsterdam Pharma serves customers in the Netherlands.

Nagrody

Aktualne wiadomości

2024-03-28 NewAmsterdam Pharma: , Including Exhibit 99.1, Is Being Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the Exchange Act ), Or Otherwise Subject To The Liability Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended (the Securities Act ). The Information Contained In This Item 7.01, Including Exhibit 99.1, Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Pursuant To The Securities Act Or Into Any Filing Or Other Document Pursuant To The Exchange Act, Except As Otherwise Expressly Stated In Any Such Filing, Financial Statements And Exhibits
2024-03-04 NewAmsterdam Pharma: , Including Exhibit 99.1, Is Being Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the Exchange Act ), Or Otherwise Subject To The Liability Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act Of 1933, As Amended (the Securities Act ). The Information Contained In This Item 7.01, Including Exhibit 99.1, Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Pursuant To The Securities Act Or Into Any Filing Or Other Document Pursuant To The Exchange Act, Except As Otherwise Expressly Stated In Any Such Filing, Financial Statements And Exhibits
2024-02-28 NewAmsterdam Pharma: Of This Current Report On Form, Financial Statements And Exhibits
2024-02-13 NewAmsterdam Pharma: The Information Contained In This Item 7.01, Including Exhibits 99.1 And 99.2, Is Being Furnished And Shall Not Be Deemed Filed For Purposes Of Section 18 Of The Securities Exchange Act Of 1934, As Amended (the Exchange Act ), Or Otherwise Subject To The Liability Of That Section Or Sections 11 And 12(a)(2) Of The Securities Act. The Information Contained In This Item 7.01, Including Exhibits 99.1 And 99.2, Shall Not Be Incorporated By Reference Into Any Registration Statement Or Other Document Pursuant To The Securities Act Or Into Any Filing Or Other Document Pursuant To The Exchange Act, Except As Otherwise Expressly Stated In Any Such Filing, Financial Statements And Exhibits
2024-01-22 NewAmsterdam Pharma: Regulation Fd Disclosure, Financial Statements And Exhibits
Wszystkie aktualności organizacji

Dokumenty

Sprawozdania MSSF / US GAAP

2023
IV kw. ang.
2022
IV kw. ang.
Pokaż wszystkie Ukryj
Należy się zalogować
Potrzebny jest dostęp

Akcje

Dług obligacyjny wg walut

Pokaż wszystko Ukryj

Kody

  • LEI
    984500B6549TF6E14D36
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001936258

Ratingi kredytowe i ESG

Makroekonomia

Należy zarejestrować się , aby uzyskać dostęp.